Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.
2.
3.

Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.

Caslake R, Macleod A, Ives N, Stowe R, Counsell C.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006661. doi: 10.1002/14651858.CD006661.pub2. Review.

PMID:
19821381
4.

Monoamine Oxidase B Inhibitors in Parkinson's Disease.

Dezsi L, Vecsei L.

CNS Neurol Disord Drug Targets. 2017;16(4):425-439. doi: 10.2174/1871527316666170124165222. Review.

PMID:
28124620
5.

Monoamine oxidase B inhibitors for early Parkinson's disease.

Macleod AD, Counsell CE, Ives N, Stowe R.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004898. Review.

PMID:
16034956
6.

Recent developments in the pharmacological treatment of Parkinson's disease.

Tuite P, Riss J.

Expert Opin Investig Drugs. 2003 Aug;12(8):1335-52. Review.

PMID:
12882620
7.

Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.

Guay DR.

Am J Geriatr Pharmacother. 2006 Dec;4(4):330-46. Review.

PMID:
17296539
8.

Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.

Fernandez HH, Chen JJ.

Pharmacotherapy. 2007 Dec;27(12 Pt 2):174S-185S. Review.

PMID:
18041937
9.
10.

Early pharmacologic treatment in Parkinson's disease.

Hauser RA.

Am J Manag Care. 2010 Mar;16 Suppl Implications:S100-7. Review.

11.

Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease.

Petzer JP, Castagnoli N Jr, Schwarzschild MA, Chen JF, Van der Schyf CJ.

Neurotherapeutics. 2009 Jan;6(1):141-51. doi: 10.1016/j.nurt.2008.10.035. Review.

12.
13.

Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.

Fernandez HH, Chen JJ.

Clin Neuropharmacol. 2007 May-Jun;30(3):150-68. Review.

PMID:
17545750
14.

Current and experimental treatments of Parkinson disease: A guide for neuroscientists.

Oertel W, Schulz JB.

J Neurochem. 2016 Oct;139 Suppl 1:325-337. doi: 10.1111/jnc.13750. Epub 2016 Aug 30. Review.

15.

Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease.

Robakis D, Fahn S.

CNS Drugs. 2015 Jun;29(6):433-41. doi: 10.1007/s40263-015-0249-8. Review.

PMID:
26164425
16.

Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.

Schapira AH.

CNS Drugs. 2011 Dec 1;25(12):1061-71. doi: 10.2165/11596310-000000000-00000. Review.

PMID:
22133327
17.

Treatment Strategies in Early Parkinson's Disease.

Marsili L, Marconi R, Colosimo C.

Int Rev Neurobiol. 2017;132:345-360. doi: 10.1016/bs.irn.2017.01.002. Epub 2017 Feb 16. Review.

PMID:
28554414
18.

New considerations in the medical management of early Parkinson's disease: impact of recent clinical trials on treatment strategy.

Hauser RA.

Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S17-21. doi: 10.1016/S1353-8020(09)70772-2. Review.

PMID:
20082983
19.

Pharmacotherapy for Parkinson's disease.

Chen JJ, Swope DM.

Pharmacotherapy. 2007 Dec;27(12 Pt 2):161S-173S. Review.

PMID:
18041936
20.

Advances in the pharmacologic management of early Parkinson disease.

Hauser RA, Zesiewicz TA.

Neurologist. 2007 May;13(3):126-32. Review.

PMID:
17495756

Supplemental Content

Support Center